Latest Reimbursement News

Phoslock Environmental Technologies has amended its December 2025 quarterly report to correct funding data and withdraw its sales outlook, while reporting improved cash flow and resuming factory operations.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Phoslock Environmental Technologies has reversed its cashflow deficits with a quarterly surplus, resumed factory operations after a long pause, and is gearing up for significant sales growth in 2026.

EBR Systems reported a doubling of WiSE System implants in Q4 FY2025 alongside the launch of key clinical studies and preliminary revenue guidance, signalling strong commercial and clinical momentum.

Everest Metals Corporation has officially commenced mining operations at its Mt Dimer Taipan Gold Project in Western Australia, backed by a fully funded agreement with MEGA Resources. Ore extraction is underway with processing set to begin in March 2026, positioning the company for near-term cash flow.

UC San Diego Health has begun clinical use of 4DMedical’s CT – VQ™, marking the fourth leading US academic medical centre to adopt this innovative lung imaging technology since FDA clearance. This milestone underscores 4DMedical’s rapid commercial traction and growing influence in respiratory diagnostics.

Adherium Limited has exceeded its 2025 shipment goals by delivering over 4,600 Hailie® Smartinhaler® devices, including more than 2,000 to Remote Patient Monitoring patients, signaling robust operational momentum.

Artrya Limited has signed a significant five-year commercial agreement with Cone Health, marking its third U.S. customer and solidifying its foothold in the American healthcare market with its AI-powered Salix platform.

Telix Pharmaceuticals reports positive Phase 3 results for its prostate cancer imaging agent Illuccix in China, paving the way for a near-term regulatory submission. Meanwhile, the company advances FDA resubmissions for its glioma and kidney cancer imaging candidates.

Cleo Diagnostics has raised $5 million to support the U.S. commercial launch of its Pre-Surgical Ovarian Cancer Test and accelerate development of a mass screening test, signaling strong investor confidence in its technology.

Sierra Nevada Gold (ASX – SNX) has won the rights to explore the expansive As Safra copper-gold project in Saudi Arabia, marking a strategic expansion into a high-potential mining district aligned with the Kingdom’s Vision 2030 ambitions.

Bulletin Resources has sold three non-core tenements of its Lake Rebecca Gold Project to Ramelius Resources for $500,000, enabling a strategic focus on its larger, recently acquired gold ground. The company remains well funded and is advancing exploration plans on high-potential targets.